Andere Sprachen ARS Pharmaceuticals, Inc.

Aktien

A2QHK9

US82835W1080

SPRY

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
9,75 ^USD	+3,07 %		+16,77 %	+77,92 %

30.04.	ARS Pharmaceuticals, Inc. reicht Antwort für Neffy (Epinephrin-Nasenspray) Zulassungsantrag beim CHMP der EMA ein	CI
30.04.	Ars Pharmaceuticals, Inc. schließt exklusive Lizenz- und Vertriebsvereinbarung mit CSL Seqirus für die Vermarktung von Neffy in Australien und Neuseeland	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand	30.04.
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	30.04.
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	30.04.
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18.04.
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18.04.
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	10.04.
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03.04.
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	03.04.
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03.04.
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03.04.
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03.04.
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21.03.
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	18.03.
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day	08.03.
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day	07.03.
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024	06.03.
North American Morning Briefing : Stock Futures -2-	06.03.
ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	27.02.
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ARS Pharmaceuticals, Inc.

Aktien

A2QHK9

US82835W1080

SPRY

Andere Sprachen

Filter